The Doctor's Lounge

The Doctor's Lounge
  • 0,0 (0)
  • Entrepreneuriat

Where scalpels meet systems — and physicians say what they really think. Co-hosted by Anish Koka, MD & Anthony DiGiorgio, DO. Candid talks on healthcare policy, reform, physician autonomy & patient care.

  1. -2 j

    Cremieux on FDA Reform, Fake Data, and the Columbia Admissions Hack

    Episode SummaryDrs. Anish Koka and Anthony DiGiorgio sit down with independent science writer Cremieux, the pseudonymous Substack author known for auditing primary data and calling out flawed research. The conversation ranges from FDA drug approval reform (Cremieux proposes a two-pathway system separating safety approval from insurer-facing efficacy approval), the divide between well-evidenced GLP-1s and unregulated peptides like BPC-157, and the HRT black-box warning controversy, to the Columbia and NYU admissions data leaks that made national news and implicated NYC mayor Zohran Mamdani. The back half digs into research methodology: why observational studies rarely replicate RCT findings, how Cremieux debunked a widely-cited Jonathan Haidt social media/cognition study, why the "administrator growth" chart doctors love to cite is likely exaggerated, and how publication bias correction methods work. Chapter Markers00:00 Introduction and guest background 02:00 Why the pseudonym "Cremieux" 03:11 How he got into primary data analysis and writing 04:46 FDA drug approval reform — a two-pathway proposal 05:57 The peptide market: GLP-1s vs. unproven peptides like BPC-157 09:39 Should drug authority come from the FDA or "bubble up" from trusted voices? 11:25 Regulatory capture and ideas for FDA reform 16:10 HRT, the black box warning, and communicating risk to patients 21:40 Decentralizing medical decision-making 22:45 DEI in medicine and the Columbia/NYU admissions data leak 34:28 Proving discrimination: causal inference standards for university admissions 36:42 Busting myths from observational studies with multiverse analysis 40:29 Debunking the Jonathan Haidt social media/cognition study 46:46 Does the US healthcare system explain lower life expectancy? 49:56 Is the administrator-to-physician growth chart accurate? 54:22 How publication bias correction methods work Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Mr. Jordan Lasker X Handle / Substack X handle: https://x.com/cremieuxrecueil Substack: https://substack.com/@cremieux

  2. 11 juil.

    Scott Becker on Building Becker's Healthcare, Physician Supply, and Private Enterprise

    Episode SummaryAnish Koka and Anthony DiGiorgio sit down with Scott Becker, founder of Becker's Healthcare and partner at McGuireWoods, on the business of medicine — his path from healthcare lawyer to media mogul, the real story behind physician supply shortages, why private enterprise (not government) is driving healthcare's real progress, and the debate over breaking up consolidated hospital systems. Chapter Markers00:00 Welcome and introducing Scott Becker 01:22 Origin story: building Becker's Healthcare 09:53 The "teach and entertain" media philosophy 14:57 Law school with Barack Obama 16:57 Physician supply and the ACA's coverage-without-supply gap 19:48 Healthcare inflation and third-party payment 24:41 Is there really a spine surgeon shortage? 37:10 Physician burnout, autonomy, and leaving clinical medicine 41:08 Reagan, Mamdani, and government vs. private healthcare 46:00 Pushing back: is "nothing we can do" a real answer? 48:30 340B reform, site-neutral payments, hospital margins 53:41 Lina Khan, Mark Cuban, and health system consolidation 57:18 Can private industry absorb hospital revenue losses? 1:04:47 Payers as the real customer, price transparency 1:06:16 Keeping Becker's Healthcare editorially independent 1:13:44 Closing thoughts and the new book Co-Host Handle @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Resource: Dr. Scott Becker Book:Building Great Businesses: Create Momentum, Overcome Setbacks, and Scale with Confidence — Scott Becker & Molly Gamble https://www.amazon.com/Building-Great-Businesses-Momentum-Confidence/dp/1637635400 Becker's Healthcare: https://www.beckershospitalreview.com/ Scott Becker on X: @becker_sbecker Becker's Healthcare Show Handle: @BeckersHR

  3. 7 juil.

    Martin Shkreli on Drug Pricing, Prison, and the Fraud That Shook Pharma

    Episode SummaryAnish Koka and Anthony DiGiorgio sit down with Martin Shkreli — the former hedge fund manager and pharma executive best known for the 2015 Daraprim price increase and his subsequent prison sentence — for a wide-ranging conversation on drug pricing, patent law, and the state of the pharmaceutical industry. Shkreli walks through his path from a teenage hedge fund intern to founding Retrophin and Turing Pharmaceuticals, defends orphan drug economics and the Orphan Drug Act's seven-year exclusivity window, and argues that patent terms haven't kept pace with the realities of modern drug development. The conversation turns to the Chemocentrics/Amgen scandal — in which trial data for a rare vasculitis drug was allegedly unblinded, manipulated, and relocked to manufacture statistical significance — which Shkreli calls one of the worst frauds in the history of medicine. The episode closes with discussion of the Sarepta/DMD approval controversy, the limits of randomized trials in surgery and rare disease, AI's parallels to neuroscience, and the state of media coverage of the FDA. Chapter Markers00:00 Intro and Martin Shkreli's backstory 02:40 Origin story: from hedge fund to founding drug companies 07:58 The Daraprim price increase and Shkreli's pricing philosophy 17:14 What it actually takes to bring a drug to market 35:25 The case for the pharmaceutical industry 38:00 The Orphan Drug Act and patent exclusivity 57:31 The Chemocentrics scandal: manipulated trial data at Amgen 1:22:09 Vinay Prasad, Sarepta, and the DMD approval fights 1:34:35 Neurosurgery, clinical trials, and the limits of RCTs 1:37:30 AI, neural networks, and the future of psychiatric drugs 1:40:40 Cardiovascular disease and LDL lowering 1:42:28 Media coverage of the FDA and closing thoughts Co-Host Handles @anish_koka and @drdigiorgio Show Handles @drsloungepod Subscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod

  4. 6 juil.

    Do No Harm: Inside the Fight to Get Identity Politics Out of Medicine

    Episode SummaryDr. Stanley Goldfarb — nephrologist, former Associate Dean for Curriculum at Penn's Perelman School of Medicine, and founder of Do No Harm — joins Drs. Koka and DiGiorgio to trace how medical education drifted from clinical science toward social activism. Goldfarb recounts the battles at Penn that led to his 2019 WSJ op-ed, the professional fallout that followed, and why he built Do No Harm into a 54,000-member organization with an active litigation strategy. The conversation covers DEI in admissions, implicit bias training, gender-affirming care in minors, nonprofit hospital tax exemption, and what it actually takes to change entrenched institutions through legislation and the courts. Chapter Markers00:00 Introduction — Dr. Stanley Goldfarb 01:37 The 2019 Wall Street Journal op-ed 12:57 The tweet that ended his relationship with Penn and UpToDate 17:04 What 550 FOIA requests revealed about who's driving DEI in academia 21:01 Is there a case for modernizing the medical curriculum? 27:29 How students gained control of the agenda 32:10 How admissions committees began selecting for activists 36:34 The two missions of Do No Harm 47:18 Nonprofit hospital tax exemption and ideological spending 53:44 The constitutional framework 1:07:19 Do demographic quotas ever make sense? 1:09:31 Closing — how to get involved with Do No Harm ResourcesBooks Doing Great Harm (2025) — Amazon: https://www.amazon.com/Doing-Great-Harm-Infecting-Healthcare_and/dp/B0FD3ZP9WN Take Two Aspirin and Call Me By My Pronouns (2022) — Amazon: https://www.amazon.com/s?k=Take+Two+Aspirin+Call+Me+By+My+Pronouns+Goldfarb Articles & Op-Eds 2019 WSJ op-ed: https://www.wsj.com/articles/take-two-aspirin-and-call-me-by-my-pronouns-11568325291 City Journal archive: https://www.city-journal.org/person/stanley-goldfarb Do No Harm: https://donoharmmedicine.org Follow Dr. Goldfarb X: https://x.com/donoharm?lang=en Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod

  5. 2 juil.

    The Myocarditis Double Standard: COVID, the Vaccine, and the Pediatric Deaths That Went Unreported

    Episode SummaryDr. Tracy Beth Høeg returns alongside Dr. Venkatesh Murthy, NIH-funded cardiologist at the University of Michigan, to dissect the Senator Ron Johnson congressional memo detailing pediatric deaths following COVID-19 vaccination — deaths the FDA's own pharmacovigilance team flagged internally but never disclosed publicly. The conversation covers the well-documented double standard applied to COVID myocarditis versus vaccine myocarditis, how journal editors killed papers not for scientific flaws but out of fear of social media backlash, why Korea's autopsy data revealed fatal cases that would never have been identified otherwise, the post-marketing commitment failures by Pfizer and Moderna, and what it means that we are still annually approving a vaccine with no randomized controlled trial evidence of clinical benefit in the current immune landscape. Chapter Markers00:00 Introduction: Why Dr. Høeg Is Back and What the Ron Johnson Memo Reveals 02:03 How Vaccine Myocarditis First Surfaced: Israel, the U.S. Military, and Early Warning Signs 05:36 Dr. Murthy on the Biology: Why the mRNA Vaccine Produced Cardiac Inflammation in a Different Population Than Expected 10:36 The Puntmann Paper: Statistical Problems, Confounding, and the Push to Close Schools and Cancel Sports 13:58 The Double Standard in Real Time: Subclinical MRI Findings vs. Kids Presenting With Chest Pain 16:26 Risk-Benefit Mismatch: Vaccine Myocarditis in Young Males vs. Genuine COVID Risk in That Population 21:05 Dr. Høeg's VAERS Analysis: Rates of One in Five Thousand, What the FDA's Own Data Showed, and the Paper That Almost Never Ran 24:03 Dr. Murthy Reveals: He Was a Reviewer for a Journal That Killed This Paper for Political Reasons 28:23 Inconsistency of Vaccine Skeptics: Who Was Questioning the Trials Before Election Day 35:52 Korea's Autopsy Program and Why the U.S. Has No Comparable Surveillance System 40:21 The Chikungunya Vaccine Withdrawal: One Death, One Action — and the Contrast With COVID 42:34 Inside the FDA: The OBPV Memo, the 10 Probable/Possible Deaths in Children, and What Happened Next 53:30 Senator Johnson's Subpoena and Why the Number Dropped from 10 to 7 58:20 Causal Attribution Double Standard: COVID Deaths vs. Vaccine Deaths 1:20:59 Should the COVID Vaccine Still Be Approved? Dr. Høeg on the Absence of Clinical Efficacy Evidence 1:23:31 The CDC-Blocked Study, Healthy Vaccinee Bias, and the Limits of Observational Data 1:28:08 What FDA Approval Actually Means — and What It Should Mean Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod

  6. 27 juin

    David Zweig on Schools, Science, and the Media's COVID Failure

    Episode SummaryInvestigative journalist David Zweig joins Anish Koka and Anthony DiGiorgio to discuss his book An Abundance of Caution: American Schools, The Virus, and a Story of Bad Decisions — a heavily cited account of how public health authorities, the media, and a politically homogenous expert class got COVID policy badly wrong, especially for children. The conversation covers why U.S. media coverage was uniquely alarmist compared to the rest of the world, how Americans overestimated child COVID mortality by as much as 40 times, the role of "technological solutionism" in making school closures possible when they never would have been before, and what it would actually take to rebuild public trust in institutions that squandered it. The episode opens with a discussion of MidJourney's foray into medical imaging and what it reveals about AI hype cycles in medicine. Resource: David's Book: https://www.amazon.com/Abundance-Caution-American-Schools-Decisions/dp/0262053993 Chapter Markers00:00 Welcome and intro: David Zweig 01:14 MidJourney enters medical imaging — hype or breakthrough? 05:35 Incidentalomas, cash-pay scanning, and who bears the cost 08:55 Ultrasound physics and why AI won't replace radiologists yet 14:00 Transition to the book: An Abundance of Caution 17:00 The Twitter Files and Zweig's COVID journalism 23:00 Political monoculture in public health and legacy media 41:43 Sweden, BLM protests, and the shifting COVID rules 43:06 The empirics on children: what the data actually showed 50:29 American media's uniquely alarmist pandemic coverage 56:31 Living in a deep blue area: why data couldn't penetrate the narrative 58:18 Anthony's ICU story and the Gellman Amnesia moment 59:50 How do we rebuild trust in public health? 1:08:28 Technological solutionism: why school closures were impossible before Zoom 1:10:07 1950s flu epidemics — schools stayed open with 50% of kids out sick 1:25:20 Newsroom monoculture, book publishing, and the conservative imprint problem 1:28:08 Reforming institutions vs. questioning their foundations 1:36:39 Wrap-up: the pandemic as a case study in how society functions Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod

  7. 20 juin

    Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch

    Episode Summary Ryan Long — former senior policy advisor to Speaker Kevin McCarthy and current non-resident senior scholar at the USC Schaefer Institute — joins Drs. Koka and DiGiorgio for a deep dive into the structural failures driving American drug pricing. The conversation covers the list-to-net price bubble and why patients pay cost-sharing on a fictitious number, how the IRA's price-setting mechanism disincentivizes both new drug development and subsequent indications, and why the 340B program — sold politically as a lifeline for safety net hospitals — systematically funnels the most money to wealthy health systems with high commercial payer mixes. Long argues the fix isn't tweaking the formula; it's scrapping the drug arbitrage mechanism entirely and replacing it with a direct, transparent grant program that actually reaches the hospitals that need it. Chapter Markers 00:00 Introduction — Ryan Long's 25 Years in Health Policy 02:08 Drug Pricing 101: List Price vs. Net Price and Why It Matters 06:39 GLP-1s as a Case Study: Insurance Pullback and the Price War That Followed 11:17 The Medicare Bridge Program and Government Price Setting for GLP-1s 14:11 Why Drug Companies Set List Prices High at Launch 16:10 The Inflation Reduction Act: Price Controls, Rebate Penalties, and Innovation Risk 20:57 Brand-to-Brand Competition and the FDA's Role 28:52 GLP-1s Under Medicare: Is the $50/Month Bridge Program Good Policy? 36:50 The Medicaid Drug Rebate Program and the Best Price Provision 38:08 The Origins of 340B: What the Program Was Actually Designed to Do 42:24 Qui Bono — How 340B Revenue Is Really Generated 50:17 Contract Pharmacies and the For-Profit Middlemen in 340B 56:31 The Humira Biosimilar Case and the Rebate Trap 1:02:58 The 1987 Supreme Court Case That Supercharged the Rebate Structure 1:05:26 Broad Reform Proposals: From 340B Overhaul to Consolidation 1:09:19 Closing Thoughts and Where to Find Ryan's Work Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod

  8. 10 juin

    The Atom Bomb Speaks: Tracy Høeg on COVID, Myocarditis, and the FDA From the Inside

    Episode SummaryDr. Tracy Høeg — physician, epidemiologist, and former Acting Director of the FDA's Center for Drug Evaluation and Research — joins Drs. Koka and DiGiorgio for her first interview since being fired from the agency in May 2025. She traces her unusual path from ophthalmology dropout to professional ultramarathoner to one of the most consequential and contested researchers of the COVID era, walking through her school transmission studies, the myocarditis preprint that detonated on social media, and what she actually found when she got inside the FDA: career scientists who were sharp, collegial, and largely aligned with her — not the entrenched bureaucratic resistance she expected. She also gives the most detailed account yet of how her firing went down, why she refused to resign, and what she thinks it signals about pharmaceutical industry influence over the agency. Chapter Markers00:00 Introduction and Tracy's bio 02:19 Origin story: French major, med school, ophthalmology dropout 07:42 Seven years in Denmark: PhD, clinical work, ultra marathon racing 10:55 Back to the US: PM&R, interventional spine, and the start of COVID research 13:43 Funding research outside the NIH pipeline 17:18 How government funding crowds out independent science 20:59 Evidence-based medicine, spine, and the N-of-one problem 25:35 The Wisconsin school transmission study 28:32 If masks were a drug, would they pass FDA approval? 30:04 Testifying before Congress three times 32:46 The myocarditis preprint: origins, backlash, and vindication 38:34 Post-vaccine myocarditis: what the data actually showed 43:01 Regulatory failure, COVID vaccine risk-benefit, and the pediatric question 45:09 How Europe and Scandinavia got it right earlier 47:58 Cancel culture in academia and the chilling effect on scientific questions 51:18 Joining the FDA: how it happened and what she expected 53:50 What the FDA looks like from the inside vs. the outside 56:38 Where real philosophical disagreements lived within the agency 58:58 Reducing animal testing and CNPV pilot: what actually got done 1:01:45 Leaks to the media: where they came from and what they meant 1:05:17 What the FDA's role should be 1:06:23 Pharmaceutical industry influence and the Wall Street Journal editorial board 1:14:48 The firing: why she refused to resign 1:18:53 The chain of command and who is responsible 1:21:08 What the firing signals about FDA reform 1:27:42 Advice for anyone thinking about taking a leadership role in government Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Resource link: Anish's substack: https://open.substack.com/pub/anishkokamd/p/they-were-fixing-the-fda-then-they?r=6chj5&utm_campaign=post-expanded-share&utm_medium=web Subscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod

Tout afficher (69)

À propos

Where scalpels meet systems — and physicians say what they really think. Co-hosted by Anish Koka, MD & Anthony DiGiorgio, DO. Candid talks on healthcare policy, reform, physician autonomy & patient care.

Informations

  • Création
    The Doctor's Lounge
  • Années d’activité
    2025 - 2026
  • Épisodes
    69
  • Classification
    Contenu explicite
  • Copyright
    © 2026 The Doctor's Lounge
  • Site web de l’émission
    The Doctor's Lounge

Vous aimeriez peut‑être aussi